FDA says all versions of Novo's GLP-1 weight loss drugs are now available
The FDA on Wednesday updated its drug shortage database to say that all dosages and versions of Novo Nordisk's Wegovy and Ozempic are now "available." A Novo spokesperson ...
View ArticleBiogen seeks growth from pipeline as investors show signs of impatience
Biogen's investors are growing restless. Wednesday's third-quarter earnings call checked most of the boxes for a successful report. The company raised its full-year guidance, and sales of its...
View ArticleAtlas of tumors reveals in 3D how cells change into cancer
The story of cancer has long started with a single mutated cell that divides and eventually grows into a tumor causing disease and death. But new research, part of a large-scale effort to map in ...
View ArticleAbbVie’s immunology blockbusters make up for Humira sales drop in Q3
AbbVie is lifting its profit outlook and full-year 2024 guidance as its immunology blockbusters Skyrizi and Rinvoq beat quarterly revenue estimates, according to the company’s third-quarter filing....
View ArticleRoche presents early-stage results for latest amyloid-based Alzheimer's attempt
Roche revealed early-stage data for a new Alzheimer’s program on Wednesday as it seeks to jump back into a field littered with failures. In a 60-patient trial testing four different doses of...
View ArticleLexeo shares early data on Alzheimer’s gene therapy
Lexeo Therapeutics shared biomarker data from 15 patients in a Phase 1/2 study of its gene therapy for Alzheimer’s disease. The hope is that the gene therapy can slow progression of ...
View ArticleCompass Pathways delays key Phase 3 psilocybin readouts, spurring 30% layoffs
Compass Pathways is pushing back the timelines of two key pivotal readouts, delaying data for a psilocybin program that's one of the leaders in psychedelic drug development. The first Phase 3 pivotal...
View ArticleCorcept misses primary endpoint in supportive Cushing's syndrome study
Corcept Therapeutics announced Wednesday that its experimental treatment for Cushing’s syndrome missed the primary endpoint in a Phase 3 trial intended to support its FDA submission. While patients...
View ArticleBristol Myers ups revenue guidance again, raising confidence in cost-cutting
Bristol Myers Squibb is lifting its 2024 financial guidance for the second straight quarter as CEO Chris Boerner’s “transition period” continues. The company is now forecasting about a 5% increase in...
View ArticleWalgreens exec Mary Langowski talks future of healthcare business
LAS VEGAS — Over the past year, Walgreens has been under pressure to turn itself around, with its stock down 65%. It plans to close 1,200 locations over the next three years ...
View ArticleAmgen makes pipeline cuts, but obesity plans remain the focus
While Amgen didn’t reveal much about upcoming readouts for its highly-anticipated weight loss drugs during third-quarter earnings, the company did detail certain changes to other parts of its pipeline....
View ArticleAnother Paragon offshoot inks reverse merger as Jade takes Aerovate’s place
Paragon Therapeutics, a company that spins out antibody biotechs, has forged a second reverse merger for its portfolio this week. Its autoimmune spinoff Jade Biosciences will take the Nasdaq spot of...
View ArticleAbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65M
AbbVie, already a leader in the T cell engager field with Epkinly and a Phase 3 program, is further digging into the field with a new discovery collaboration with EvolveImmune Therapeutics. The Chicago...
View ArticleStartup Evommune raises $115M for I&I pipeline
Another inflammation and immunology startup has attracted big bucks. On Thursday, Evommune announced a $115 million raise to back a pipeline anticipated to have multiple Phase 2 readouts in the next 18...
View ArticleHow Define Ventures has changed its approach to AI in health tech
LAS VEGAS — The dynamics of AI in health tech are changing all the time, and it’s important to adapt your thinking around it, investor Lynne Chou O’Keefe told Endpoints News in an interview on ...
View ArticleBoehringer, Gubra stop work on obesity drug; Galapagos restarts CAR-T study
Plus, news about Alnylam, Hutchmed, Wave Life Sciences and Matinas BioPharma: Boehringer Ingelheim ends work with Gubra on obesity drug: The German drugmaker stopped developing Gubra’s long-acting...
View ArticleArgenx reports Vyvgart sales streak, bolstered by launch in rare neuro disorder
Argenx’s Vyvgart has beat sales expectations for the eleventh quarter in a row, supported by strong uptake of a subcutaneous version of the drug in its newest indication. Vyvgart made $573 million in...
View ArticleTakeda says multiyear restructuring is 'on track'
Five months into a restructuring at Takeda that has led to pipeline cuts and hundreds of layoffs, CEO Christophe Weber said the company’s plans are “on track.” The Japanese ...
View ArticleWuXi in ‘early stages’ of CGT business review; Lonza exec becomes AGC Bio CEO
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. WuXi AppTec is in the “early stages” of “reviewing” its cell and gene...
View ArticleGardasil demand in China sinks, and Merck expects the same next quarter
Merck said sales of its HPV vaccine Gardasil — its second-largest product — dipped again in the third quarter, citing reduced demand in China, where the shot is only approved for females. Gardasil’s...
View Article